Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia.
US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.